

Instance: composition-en-078ce846d23a61e02d1edb518ce5e784
InstanceOf: CompositionUvEpi
Title: "Composition for bortezomib Package Leaflet"
Description:  "Composition for bortezomib Package Leaflet"
Usage: #inline

* identifier.system = ""

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - bortezomib"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  What is in this leaflet 
1. What Bortezomib Accord is and what it is used for 
2. What you need to know before you use Bortezomib Accord 
3. How to use Bortezomib Accord 
4. Possible side effects 
5. How to store Bortezomib Accord 
6. Contents of the pack and other information 
         </div>"""   
          

* section[=].section[+]
  * title =  "1. What bortezomib is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What bortezomib is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Bortezomib Accord contains the active substance bortezomib, a so-called  proteasome inhibitor . 
Proteasomes play an important role in controlling cell function and growth. By interfering with their 
function, bortezomib can kill cancer cells. </p>
<p>Bortezomib Accord is used for the treatment of multiple myeloma (a cancer of the bone marrow) in 
patients older than 18 years:</p>
<ul>
<li>alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for 
patients whose disease is worsening (progressive) after receiving at least one prior treatment and 
for whom blood stem cell transplantation was not successful or is unsuitable. </li>
<li>in combination with the medicines melphalan and prednisone, for patients whose disease has not 
been previously treated and are unsuitable for high-dose chemotherapy with blood stem cell 
transplantation. </li>
<li>in combination with the medicines dexamethasone or dexamethasone together with thalidomide, 
for patients whose disease has not been previously treated and before receiving high-dose 
chemotherapy with blood stem cell transplantation (induction treatment). </li>
</ul>
<p>Bortezomib Accord is used for the treatment of mantle cell lymphoma (a type of cancer affecting the 
lymph nodes) in patients 18 years or older in combination with the medicines rituximab, 
cyclophosphamide, doxorubicin and prednisone, for patients whose disease has not been previously 
treated and for whom blood stem cell transplantation is unsuitable. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take bortezomib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take bortezomib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Bortezomib Accord 
- if you are allergic to bortezomib, boron or to any of the other ingredients of this medicine (listed 
in section 6) 
- if you have certain severe lung or heart problems. </p>
<p>Warnings and precautions 
You should tell your doctor if you have any of the following: 
* low numbers of red or white blood cells 
* bleeding problems and/or low number of platelets in your blood 
* diarrhoea, constipation, nausea or vomiting 
* fainting, dizziness or light-headedness in the past 
* kidney problems 
* moderate to severe liver problems 
* numbness, tingling, or pain in the hands or feet (neuropathy) in the past 
* heart or blood pressure problems 
* shortness of breath or cough 
* seizures 
* shingles (localised including around the eyes or spread across the body) 
* symptoms of tumor lysis syndrome such as muscle cramping, muscle weakness, confusion, 
visual loss or disturbances and shortness of breath 
* memory loss, trouble thinking, difficulty with walking or loss of vision. These may be signs of a 
serious brain infection and your doctor may suggest further testing and follow-up. </p>
<p>You will have to take regular blood tests before and during your treatment with Bortezomib Accord, to 
check your blood cell counts regularly. </p>
<p>If you have mantle cell lymphoma and are given the medicine rituximab with Bortezomib Accord you 
should tell your doctor: 
* if you think you have hepatitis infection now or have had it in the past. In a few cases, patients 
who have had hepatitis B might have a repeated attack of hepatitis, which can be fatal. If you 
have a history of hepatitis B infection you will be carefully checked by your doctor for signs of 
active hepatitis B. </p>
<p>You must read the package leaflets of all medicines to be taken in combination with Bortezomib 
Accord for information related to these medicines before starting treatment with Bortezomib Accord. 
When thalidomide is used, particular attention to pregnancy testing and prevention requirements is 
needed (see Pregnancy and breast-feeding in this section). </p>
<p>Children and adolescents 
Bortezomib Accord should not be used in children and adolescents because it is not known how the 
medicine will affect them. </p>
<p>Other medicines and Bortezomib Accord 
Please tell your doctor, or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>In particular, tell your doctor if you are using medicines containing any of the following active 
substances:</p>
<ul>
<li>ketoconazole, used to treat fungal infections </li>
<li>ritonavir, used to treat HIV infection </li>
<li>rifampicin, an antibiotic used to treat bacterial infections </li>
<li>carbamazepine, phenytoin or phenobarbital used to treat epilepsy </li>
<li>St. John s Wort (Hypericum perforatum), used for depression or other conditions </li>
<li>oral antidiabetics </li>
</ul>
<p>Pregnancy and breast-feeding 
You should not use Bortezomib Accord if you are pregnant, unless clearly necessary. </p>
<p>Both men and women receiving Bortezomib Accord must use effective contraception during and for 
up to 3 months after treatment. If, despite these measures, pregnancy occurs, tell your doctor 
immediately. </p>
<p>You should not breast-feed while using Bortezomib Accord. Discuss with your doctor when it is safe 
to restart breast-feeding after finishing your treatment. </p>
<p>Thalidomide causes birth defects and foetal death. When Bortezomib Accord is given in combination 
with thalidomide you must follow the pregnancy prevention programme for thalidomide (see package 
leaflet for thalidomide). </p>
<p>Driving and using machines 
Bortezomib Accord might cause tiredness, dizziness, fainting, or blurred vision. Do not drive or 
operate tools or machines if you experience such side effects; even if you do not, you should still be 
cautious. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take bortezomib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take bortezomib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Your doctor will work out your dose of Bortezomib Accord according to your height and weight (body 
surface area). The usual starting dose of Bortezomib Accord is 1.3 mg/m2 body surface area twice a 
week. </p>
<p>Your doctor may change the dose and total number of treatment cycles, depending on your response to 
the treatment on the occurrence of certain side effects and on your underlying conditions (e.g. liver 
problems). </p>
<p>Progressive multiple myeloma 
When Bortezomib Accord is given alone, you will receive 4 doses of Bortezomib Accord 
intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a 10-day  rest period  without 
treatment. This 21-day period (3 weeks) corresponds to one treatment cycle. You might receive up to 
8 cycles (24 weeks). </p>
<p>You may also be given Bortezomib Accord together with the medicines pegylated liposomal 
doxorubicin or dexamethasone. </p>
<p>When Bortezomib Accord is given together with pegylated liposomal doxorubicin, you will receive 
Bortezomib Accord intravenously or subcutaneously as a 21-day treatment cycle and pegylated 
liposomal doxorubicin 30 mg/m2 is given on day 4 of the Bortezomib Accord 21-day treatment cycle 
as an intravenous infusion after the Bortezomib Accord injection. 
You might receive up to 8 cycles (24 weeks). </p>
<p>When Bortezomib Accord is given together with dexamethasone, you will receive Bortezomib Accord 
intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 20 mg is given orally 
on days 1, 2, 4, 5, 8, 9, 11, and 12, of the Bortezomib Accord, 21-day treatment cycle. 
You might receive up to 8 cycles (24 weeks). </p>
<p>Previously untreated multiple myeloma 
If you have not been treated before for multiple myeloma, and you are not suitable for blood stem cell 
transplantation you will receive Bortezomib Accord together with two other medicines; melphalan and 
prednisone. </p>
<p>In this case, the duration of a treatment cycle is 42 days (6 weeks). You will receive 9 cycles 
(54 weeks). 
* In cycles 1 to 4, Bortezomib Accord is administered twice weekly on days 1, 4, 8, 11, 22, 25, and 32. * In cycles 5 to 9, Bortezomib Accord is administered once weekly on days 1, 8, 22 and 2</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Melphalan (9 mg/m2) and prednisone (60 mg/m2) are both given orally on days 1, 2, 3 and 4 of the 
first week of each cycle. </p>
<p>If you have not been treated before for multiple myeloma, and you are suitable for blood stem cell 
transplantation you will receive Bortezomib Accord intravenously or subcutaneously together with the 
medicines dexamethasone, or dexamethasone and thalidomide, as induction treatment. </p>
<p>When Bortezomib Accord is given together with dexamethasone, you will receive Bortezomib Accord 
intravenously or subcutaneously as a 21-day treatment cycle and dexamethasone 40 mg is given orally 
on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib Accord 21-day treatment cycle. 
You will receive 4 cycles (12 weeks). </p>
<p>When Bortezomib Accord is given together with thalidomide and dexamethasone, the duration of a 
treatment cycle is 28 days (4 weeks). </p>
<p>Dexamethasone 40 mg is given orally on days 1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib Accord 
28-day treatment cycle and thalidomide is given orally daily at 50 mg up to day 14 of the first cycle, 
and if tolerated the thalidomide dose is increased to 100 mg on days 15-28 and may be further 
increased to 200 mg daily from the second cycle onwards. </p>
<p>You might receive up to 6 cycles (24 weeks). </p>
<p>Previously untreated mantle cell lymphoma 
If you have not been treated before for mantle cell lymphoma, you will receive Bortezomib Accord 
intravenously or subcutaneously together with the medicines rituximab, cyclophosphamide, 
doxorubicin and prednisone. </p>
<p>Bortezomib Accord is given intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a 
 rest period  without treatment. The duration of a treatment cycle is 21 days (3 weeks). You might 
receive up to 8 cycles (24 weeks). </p>
<p>The following medicines are given on day 1 of each Bortezomib Accord 21-day treatment cycle as 
intravenous infusions: 
Rituximab at 375 mg/m2, cyclophosphamide at 750 mg/m2 and doxorubicin at 50 mg/m2. Prednisone is given orally at 100 mg/m2 on days 1, 2, 3, 4 and 5 of the Bortezomib Accord treatment 
cycle. </p>
<p>How Bortezomib Accord is given 
Bortezomib Accord will be administered by a health care professional experienced in the use of 
cytotoxic medicines. </p>
<p>This medicine is for subcutaneous use (injected under the skin) and, after dilution, also for intravenous 
use (injected into a vein). Injection into a vein is rapid, taking 3 to 5 seconds. Injection under the skin 
is in either the thighs or the abdomen. </p>
<p>If you are given too much Bortezomib Accord 
As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much. 
In the unlikely event of an overdose, your doctor will monitor you for side effects. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store bortezomib"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store bortezomib"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of 
these effects may be serious. </p>
<p>If you are given Bortezomib Accord for multiple myeloma or mantle cell lymphoma, tell your doctor 
straight away if you notice any of the following symptoms:</p>
<ul>
<li>muscle cramping, muscle weakness </li>
<li>confusion, visual loss or disturbances, blindness, seizures, headaches </li>
<li>shortness of breath, swelling of your feet or changes in your heart beat, high blood pressure, 
tiredness, fainting </li>
<li>coughing and breathing difficulties or tightness in the chest. </li>
</ul>
<p>Treatment with Bortezomib Accord can very commonly cause a decrease in the numbers of red and 
white blood cells and platelets in your blood. Therefore, you will have to take regular blood tests 
before and during your treatment with Bortezomib Accord, to check your blood cell counts regularly. 
You may experience a reduction in the number of:</p>
<ul>
<li>platelets, which may make you be more prone to bruising, or to bleeding without obvious injury 
(e.g., bleeding from your bowels, stomach, mouth and gum or bleeding in the brain or bleeding 
from the liver) </li>
<li>red blood cells, which can cause anaemia, with symptoms such as tiredness and paleness </li>
<li>white blood cells may make you more prone to infections or flu-like symptoms. </li>
</ul>
<p>If you are given Bortezomib Accord for the treatment of multiple myeloma the side effects you may 
get are listed below: </p>
<p>Very common side effects (may affect more than 1 in 10 people) 
* Sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet, due 
to nerve damage 
* Reduction in the number of red blood cells and or white blood cells (see above) 
* Fever 
* Feeling sick (nausea) or vomiting, loss of appetite 
* Constipation with or without bloating (can be severe) 
* Diarrhoea: if this happens, it is important that you drink more water than usual. Your doctor 
may give you another medicine to control diarrhoea 
* Tiredness (fatigue), feeling weak 
* Muscle pain, bone pain </p>
<p>Common side effects (may affect up to 1 in 10 people) 
* Low blood pressure, sudden fall of blood pressure on standing which may lead to fainting 
* High blood pressure 
* Reduced functioning of your kidneys 
* Headache 
* General ill feeling, pain, vertigo, light-headedness, a feeling of weakness or loss of 
consciousness 
* Shivering 
* Infections, including pneumonia, respiratory infections, bronchitis, fungal infections, coughing 
with phlegm, flu like illness 
* Shingles (localised including around the eyes or spread across the body) 
* Chest pains or shortness of breath with exercise 
* Different types of rash 
* Itching of the skin, lumps on the skin or dry skin 
* Facial blushing or tiny broken capillaries 
* Redness of the skin 
* Dehydration 
* Heartburn, bloating, belching, wind, stomach pain, bleeding from your bowels or stomach 
* Alteration of liver functioning 
* A sore mouth or lip, dry mouth, mouth ulcers or throat pain 
* Weight loss, loss of taste 
* Muscle cramps, muscle spasms, muscle weakness, pain in your limbs 
* Blurred vision 
* Infection of the outermost layer of the eye and the inner surface of the eyelids (conjunctivitis) 
* Nose bleeds 
* Difficulty or problems in sleeping, sweating, anxiety, mood swings, depressed mood, 
restlessness or agitation, changes in your mental status, disorientation 
* Swelling of body, to include around eyes and other parts of the body </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
* Heart failure, heart attack, chest pain, chest discomfort, increased or reduced heart rate 
* Failing of your kidneys 
* Inflammation of a vein, blood clots in your veins and lungs 
* Problems with blood clotting 
* Insufficient circulation 
* Inflammation of the lining around your heart or fluid around your heart 
* Infections including urinary tract infections, the flu, herpes virus infections, ear infection and 
cellulitis 
* Bloody stools, or bleeding from mucosal membranes, e.g., mouth, vagina 
* Cerebrovascular disorders 
* Paralysis, seizures, falling, movement disorders, abnormal or change in, or reduced sensation 
(feeling, hearing, tasting, smelling), attention disturbance, trembling, twitching 
* Arthritis, including inflammation of the joints in the fingers, toes, and the jaw 
* Disorders that affect your lungs, preventing your body from getting enough oxygen. Some of 
these include difficulty breathing, shortness of breath, shortness of breath without exercise, 
breathing that becomes shallow, difficult or stops, wheezing 
* Hiccups, speech disorders 
* Increased or decreased urine production (due to kidney damage), painful passing of urine or 
blood/proteins in the urine, fluid retention 
* Altered levels of consciousness, confusion, memory impairment or loss 
* Hypersensitivity 
* Hearing loss, deafness or ringing in the ears, ear discomfort 
* Hormone abnormality which may affect salt and water absorption 
* Overactive thyroid gland 
* Inability to produce enough insulin or resistance to normal levels of insulin 
* Irritated or inflamed eyes, excessively wet eyes, painful eyes, dry eyes, eye infections, lump in 
the eyelid (chalazion), red and swollen eyelids, discharge from the eyes, abnormal vision, 
bleeding of the eye 
* Swelling of your lymph glands 
* Joint or muscle stiffness, sense of heaviness, pain in your groin 
* Hair loss and abnormal hair texture 
* Allergic reactions 
* Redness or pain at the injection site 
* Mouth pain 
* Infections or inflammation of the mouth, mouth ulcers, oesophagus, stomach and intestines, 
sometimes associated with pain or bleeding, poor movement of the intestines (including 
blockage), abdominal or oesophageal discomfort, difficulty swallowing, vomiting of blood 
* Skin infections 
* Bacterial and viral infections 
* Tooth infection 
* Inflammation of the pancreas, obstruction of the bile duct 
* Genital pain, problem having an erection 
* Weight increase 
* Thirst 
* Hepatitis 
* Injection site or injection device related disorders 
* Skin reactions and disorders (which may be severe and life threatening), skin ulcers 
* Bruises, falls and injuries 
* Inflammation or haemorrhage of the blood vessels that can appear as small red or purple dots 
(usually on the legs) to large bruise-like patches under the skin or tissue 
* Benign cysts 
* A severe reversible brain condition which includes seizures, high blood pressure, headaches, 
tiredness, confusion, blindness or other vision problems. </p>
<p>Rare side effects (may affect up to 1 in 1,000 people) 
* Heart problems to include heart attack, angina 
* Serious nerve inflammation, which may cause paralysis and difficulty breathing (Guillain-Barr<br />
syndrome) 
* Flushing 
* Discolouration of the veins 
* Inflammation of the spinal nerve 
* Problems with your ear, bleeding from your ear 
* Underactivity of your thyroid gland 
* Budd Chiari syndrome (the clinical symptoms caused by blockage of the hepatic veins) 
* Changes in or abnormal bowel function 
* Bleeding in the brain 
* Yellow discolouration of eyes and skin (jaundice) 
* Serious allergic reaction (anaphylactic shock) signs of which may include difficulty breathing, 
chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised 
lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in 
swallowing, collapse 
* Breast disorders 
* Vaginal tears 
* Genital swelling 
* Inability to tolerate alcohol consumption 
* Wasting, or loss of body mass 
* Increased appetite 
* Fistula 
* Joint effusion 
* Cysts in the lining of joints (synovial cysts) 
* Fracture 
* Breakdown of muscle fibers leading to other complications 
* Swelling of the liver, bleeding from the liver 
* Cancer of the kidney 
* Psoriasis like skin condition 
* Cancer of the skin 
* Paleness of the skin 
* Increase of platelets or plasma cells (a type of white cell) in the blood 
* Blood clot in small blood vessels (thrombotic microangiopathy) 
* Abnormal reaction to blood transfusions 
* Partial or total loss of vision 
* Decreased sex drive 
* Drooling 
* Bulging eyes 
* Sensitivity to light 
* Rapid breathing 
* Rectal pain 
* Gallstones 
* Hernia 
* Injuries 
* Brittle or weak nails 
* Abnormal protein deposits in your vital organs 
* Coma 
* Intestinal ulcers 
* Multi-organ failure 
* Death </p>
<p>If you are given Bortezomib Accord together with other medicines for the treatment of mantle cell 
lymphoma the side effects you may get are listed below: </p>
<p>Very common side effects (may affect more than 1 in 10 people) 
* Pneumonia 
* Loss of appetite 
* Sensitivity, numbness, tingling or burning sensation of the skin, or pain in the hands or feet, due 
to nerve damage 
* Nausea and vomiting 
* Diarrhoea 
* Mouth ulcers 
* Constipation 
* Muscle pain, bone pain 
* Hair loss and abnormal hair texture 
* Tiredness, feeling weak 
* Fever </p>
<p>Common side effects (may affect up to 1 in 10 people) 
* Shingles (localized including around the eyes or spread across the body) 
* Herpes virus infections 
* Bacterial and viral infections 
* Respiratory infections, bronchitis, coughing with phlegm, flu like illness 
* Fungal infections 
* Hypersensitivity (allergic reaction) 
* Inability to produce enough insulin or resistance to normal levels of insulin 
* Fluid retention 
* Difficulty or problems in sleeping 
* Loss of consciousness 
* Altered level of consciousness, confusion 
* Feeling dizzy 
* Increased heartbeat, high blood pressure, sweating, 
* Abnormal vision, blurred vision 
* Heart failure, heart attack, chest pain, chest discomfort, increased or reduced heart rate 
* High or low blood pressure 
* Sudden fall of blood pressure upon standing which may lead to fainting 
* Shortness of breath with exercise 
* Cough 
* Hiccups 
* Ringing in the ears, ear discomfort 
* Bleeding from your bowels or stomach 
* Heartburn 
* Stomach pain, bloating 
* Difficulty swallowing 
* Infection or inflammation of the stomach and intestines 
* Stomach pain 
* Sore mouth or lip, throat pain 
* Alteration of liver function 
* Itching of skin 
* Redness of skin 
* Rash 
* Muscle spasms 
* Infection of the urinary tract 
* Pain in limbs 
* Swelling of body, to include eyes and other parts of the body 
* Shivering 
* Redness and pain at injection site 
* General ill feeling 
* Weight loss 
* Weight increase </p>
<p>Uncommon side effects (may affect up to 1 in 100 people) 
* Hepatitis 
* Severe allergic reaction (anaphylactic reaction) signs of which may include difficulty breathing, 
chest pain or chest tightness, and/or feeling dizzy/faint, severe itching of the skin or raised 
lumps on the skin, swelling of the face, lips, tongue and /or throat, which may cause difficulty in 
swallowing, collapse 
* Movement disorders, paralysis, twitching 
* Vertigo 
* Hearing loss, deafness<br />
* Disorders that affect your lungs, preventing your body from getting enough oxygen. Some of 
these include difficulty breathing, shortness of breath, shortness of breath without exercise, 
breathing that becomes shallow, difficult or stops, wheezing 
* Blood clots in your lungs 
* Yellow discoloration of the eyes and skin (jaundice) 
* Lump in the eyelid (chalazion), red and swollen eyelids </p>
<p>Rare side effects (may affect up to 1 in 1,000 people) 
* Blood clot in small blood vessels (thrombotic microangiopathy) 
* Serious nerve inflammation, which may cause paralysis and difficulty breathing (Guillain-Barr  </p>
<p>syndrome) </p>
<p>Reporting of side effects 
If any of the side effects, gets serious, or if you notice , any side effects not listed in this leaflet, please 
tell your doctor or pharmacist immediately. You can also report side effects directly via the national 
reporting system listed in Appendix V. By reporting side effects you can help provide more 
information on the safety of this medicine. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date stated on the vial and the carton after EXP. </p>
<p>Store in a refrigerator (2 C to 8  C).<br />
Keep the vial in the outer carton in order to protect from light. </p>
<p>Diluted solution 
The chemical and physical in-use stability of the diluted solution at a concentration of 1 mg/mL has 
been demonstrated for 24 hours at 20 C-25 C. From a microbiological point of view, unless the 
method of opening/ dilution precludes the risk of microbial contamination, the diluted solution should 
be used immediately after preparation. If not used immediately, in-use storage times and conditions 
prior to use are the responsibility of the user.  </p>
<p>Bortezomib Accord is for single use only. Any unused product or waste material should be disposed of 
in accordance with local requirements. </p>         </div>"""      

